22 September 2025 | Sydney, Australia – LTR Pharma Limited (ASX:LTP), a clinical-stage pharmaceutical company focused on rapid-acting intranasal therapies, is pleased to announce that it has secured a 33% equity stake in LevOmega Pty Ltd at no cost to shareholders. This investment provides LTR Pharma with new exposure to the global multi-billion-dollar omega-3 market, which complements the Company's core intranasal pharmaceutical programs.
LTR Pharma secures a 33% stake in LevOmega at no cost to shareholders.
LevOmega, Levur Pty Ltd, and Green Blue Health Pty Ltd, leverages cross-sector expertise in biotech, nutraceuticals, and pharmaceutical commercialisation.
Formal R&D and Licensing Agreement is now in place between LevOmega and Levur to develop nature-identical, pharmaceutical-grade omega-3 oils.
LevOmega provides LTR Pharma with access to a scalable, sustainable alternative to marine-based omega-3, addressing critical supply and quality issues in the global market.
The move aligns with LTR Pharma's strategy of developing first-in-class therapies for significant underserved markets.
Addressing a Global Supply Challenge
Omega-3 oil is widely recognised for its cardiovascular and anti-inflammatory health benefits, but traditional sources of fish oil are constrained by overfishing, pollution, and degradation of several environmental factors. Studies show that the global nutritional needs for EPA and DHA are already exceeding sustainable marine supply.
LevOmega seeks to fill this gap by developing high-purity, consistent and scalable omega-3 ingredients by using nature-identical biotechnology platforms. These new products are expected to serve both nutritional and pharmaceutical markets, as well as offer a new alternative that meets the rising demand for sustainable and clinically-validated omega-3 solutions.
Next Steps
LevOmega's pathway includes:
Technical validation of its nature-identical omega-3 oil.
Pilot-scale production of product.
Commercial launch, supplying high-grade omega-3 ingredients to manufacturers of pharmaceutical, nutraceutical, and functional food products.
This initiative adds to LTR Pharma's growing innovation platform, alongside:
SPONTAN® and ROXUS® – rapid-onset intranasal therapies for erectile dysfunction.
OROFLOW® – under development for oesophageal motility disorders.
About us:
About LTR Pharma (ASX:LTP)
LTR Pharma is a commercial-stage pharmaceutical company delivering innovative therapies for significant unmet medical needs through its proprietary intranasal drug delivery platform. The Company has successfully commercialised its rapid-acting treatment technology in Australia and is expanding access whilst advancing regulatory pathways in the US and other key markets.
LTR's lead products, SPONTAN® and ROXUS®, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is now advancing OROFLOW®, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) – a debilitating group of conditions affecting swallowing function.
Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated, patient-centric treatments that enhance quality of life.
